Trial reportBMC oral health2025
β-glycyrrhetinic acid-containing dentifrice alleviates dental plaque accumulation and gingival inflammation: a randomized, cross-over, placebo-controlled study.
Trial report in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlaque control is essential for the prevention of dental caries and periodontal diseases. β-glycyrrhetinic acid (BGA) is an anti-inflammatory compound that has also been shown to be antibacterial. This study aimed to determine the effect of a dentifrice containing BGA on supragingival dental plaque accumulation.
methodsTwenty-five patients who visited the Nagasaki University Hospital for periodontal maintenance from October 2020 to April 2022 were included in this study. It was a cross-over double-blind study, with BGA-containing and placebo toothpaste used for 1 week each. The use of toothpaste was randomly assigned using the block size 2 substitution block method. The primary endpoint was the area of plaque deposition on the margins after 1 week of toothpaste use for all teeth. The plaque deposition area was assessed using the Turesky–Gilmore–Glickmann Modification of the Quigley-Hein Plaque index (M-QHI) and statistically evaluated with a paired t-test.
resultsThe plaque deposition area of all participants was analyzed after 1 week of use of BGA-containing and placebo toothpaste. The mean M-QHI after using the BGA-containing toothpaste was 0.63 ± 0.19, which was significantly lower (p < 0.001) than the mean M-QHI after using the placebo toothpaste (0.75 ± 0.21). No significant adverse events were observed in any of the patients.
conclusionsBGA-containing dentifrices may be useful in preventing caries and periodontal disease by inhibiting the accumulation of supragingival plaques.
trial registrationThis clinical trial was registered on UMIN-CTR (UMIN000040628, A verification study on plaque formation by using a dentifrice) on June 2, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.